A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma Europe B.V.
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months

Exclusion Criteria:

• Pregnant and breastfeeding women

• Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)